FindTrial
Sign In

Comparing protein and mRNA levels in oral precancerous and healthy oral lesion . A study on Oral health risk

Evaluation of Transforming Growth Factor-ß Receptor Type II protein and mRNA expression in low-risk and high-risk Oral Leukoplakia and normal healthy mucosa- A prospective cross-sectional study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/071297
Enrollment
30
Registered
2024-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: K132- Leukoplakia and other disturbancesof oral epithelium, including tongue Health Condition 3: K132- Leukoplakia and other disturbancesof oral epithelium, including tongue

Interventions

Intervention1: NIL: NO INTERVENTION

Sponsors

MGM Dental College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Group I (control group) 1. Age and sex matched healthy oral mucosa cases. 2.Normal appearing mucosa of patients who will be undergoing crown lengthening procedure, periodontal surgery or 3rd molar impaction surgery Group II (study group) II a. Oral Leukoplakia cases with low-risk epithelial dysplasia II b. Oral Leukoplakia cases with high risk of epithelial dysplasia

Exclusion criteria

Exclusion criteria: Group I (control group) 1. Patients not willing to participate in the study. Group IIa and IIb (study group): 1.Patients with other established carcinomas. 2.Clinico-histopathologically diagnosed OPMDs other than oral leukoplakia 3. Patients who are undergoing any local/systemic treatment for Oral Leukoplakia. 4.Patients not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
To evaluate Transforming Growth Factor-ß Receptor Type II protein and mRNA expression in low-risk and high-risk Oral Leukoplakia and normal healthy mucosa. Timepoint: Expected evaluation of the study is 18 months—

Secondary

MeasureTime frame
To evaluate & compare Transforming Growth Factor-ß Receptor Type II by immunoexpression in low-risk & high-risk Oral Leukoplakia & normal healthy mucosa by qPCR. Timepoint: Expected Timeline for the evaluation of the study 18 months.—

Countries

India

Contacts

Public ContactDr Jigna Pathak

MGM Dental College and Hospital

drjignapathak@gmail.com9819175805

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026